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Endovascular Extraction of Caval Tumor Thrombus to
Facilitate Minimally Invasive Cytoreductive
Nephrectomy for Metastatic Kidney Cancer

[(Fig._1)TD$IG]

We report the first case of endovascular extraction of
inferior vena cava (IVC) tumor thrombus (IVCT) to facilitate

subsequent minimally invasive cytoreductive nephrectomy
(CN) in a patient with metastatic renal cell carcinoma
(mRCC) and IVC involvement.
A 60-yr-old man presented with hematuria and weight
loss. A computed tomography scan of the abdomen showed
an 8-cm right renal mass with level 2 IVCT and innumerable
lung nodules, consistent with mRCC. The patient desired a

Fig. 1 – (a) Schematic of the AngioVac procedure. Venous access was obtained in the right internal jugular and right common femoral veins using
26-French DrySeal sheaths (Gore Medical, Flagstaff, AZ, USA). A 22-French AngioVac suction cannula was inserted into the right internal jugular vein
sheath and positioned in the suprarenal inferior vena cava, above the tumor thrombus. An 18-French reinfusion cannula was inserted through the right
common femoral vein sheath to complete a venovenous bypass circuit. A Terumo Bubble Trap (Terumo, Tokyo, Japan) was connected to the
cardiopulmonary bypass pump head for filtration of the evacuated tumor thrombus. The AngioVac suction cannula was advanced to extract the inferior
vena cava tumor thrombus (IVCT). The patient returned 1 wk later for a simplified minimally invasive cytoreductive nephrectomy. (b) Pretreatment
magnetic resonance imaging (MRI) with the arrow showing level 2 IVCT. (c) MRI after the AngioVac procedure confirmed removal of IVCT (arrow).
IVC = inferior vena cava; L = liver; RK = right kidney.

0302-2838/# 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on April 19, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

168

EUROPEAN UROLOGY 68 (2015) 167–170

minimally invasive approach for CN and IVC thrombectomy
with early systemic therapy.
One week prior to CN, the patient underwent removal
of the IVCT using the AngioVac system (Angiodynamics,
Lathum, NY, USA), which is a percutaneous endovascular
suction thrombectomy device that operates via an extracorporeal venous bypass circuit with filtration of the blood prior
to its return to the body (Fig. 1a). The patient was heparinized,
and the AngioVac suction cannula was advanced to extract
the IVCT. Clearance of IVCT was confirmed with magnetic
resonance imaging (Fig. 1b and 1c). The patient had an
uneventful recovery and was discharged the following day.
Pathologic assessment of the removed IVCT fragments
confirmed RCC. The following week, the patient underwent
a minimally invasive CN [1]. Operating time was 239 min,
estimated blood loss was 260 ml, and the patient had an
uneventful discharge on day 2. Final pathology confirmed
Fuhrman grade IV clear cell RCC.
Surgery for IVCT has traditionally been via an open
approach, but some patients with mRCC and IVCT may not
tolerate the morbidity of an open procedure followed by
systemic therapy. Approximately 40% of patients presenting
with mRCC are managed nonoperatively [2]. Minimally
invasive surgery for IVCT has been reported by experienced
surgeons [3,4], but the need for IVC reconstruction increases
surgical complexity.
Westesson et al reported on 76 patients with mRCC and
IVCT who underwent open CN over a 22-yr period at a highvolume tertiary care center [5]. Postoperative complications
occurred in 37% of patients; six patients (7.9%) had major
postoperative complications that were fatal for five (6.6%).
Four patients required emergent pulmonary artery embolectomy, of which one patient died intraoperatively and
two patients died of disease progression before receiving
systemic therapy.
Our patient presented with RCC plus IVCT and highvolume metastases. Use of the AngioVac facilitated a
minimally invasive CN by avoiding the need for resection
of the IVCT and IVC reconstruction. Clinical implications of
our technique include the potential to offer a simplified
minimally invasive CN for patients with mRCC and IVCT
who might not otherwise be candidates for surgery.
Limitations of an endovascular approach for IVCT
removal include potential for liberation of tumor cells

into systemic circulation and inability of the current
AngioVac device to extract larger tumor thrombi. Technical
modifications to overcome these limitations would be
needed to extend indications for this technique to patients
with nonmetastatic disease or more extensive IVCT.
Although our technique is applicable to only a small subset
of patients with RCC, we feel that it provides a proof
of principle of feasibility and a platform for further
development.

Exceptional Response to Pazopanib in a Patient with
Urothelial Carcinoma Harboring FGFR3 Activating
Mutation and Amplification

ate, vinblastine, doxorubicin, and cisplatin (MVAC regimen)
chemotherapy. Her course was complicated by neutropenic
fever, and subsequent imaging showed Response Evaluation
Criteria in Solid Tumor–defined progression, with multiple
new pulmonary nodules emerging. The patient then received
a combination of doxorubicin and ifosfamide, complicated
by both neutropenic fever and renal impairment with no
documented response. This was followed by sequential
therapy with paclitaxel followed by methotrexate, gemcitabine, and cyclophosphamide. Treatment was interrupted
to allow the patient to undergo a palliative cystectomy.

We report the case of a 67-yr-old woman who presented with
intermittent gross hematuria. Cystoscopy showed a sessile
bladder tumor, and biopsy demonstrated high-grade papillary urothelial carcinoma. Computed tomography (CT)
imaging of the chest, abdomen, and pelvis revealed a 7-cm
bladder mass and multiple pulmonary nodules ranging from
0.4 to 2.1 cm. The patient received four cycles of methotrex-
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